The Future of AI and Drug Development: Insights from Absci’s Sean McClain and Andreas Busch

In this episode of FYI, Brett Winton and Charlie Roberts sit down with Sean McClain, CEO and founder of Absci, and Andreas Busch, Absci's Chief Innovation Officer, to explore how AI is transforming drug discovery and development, particularly in the biologic space. Sean shares how Absci is using AI to tackle the design problem in drug discovery, unlocking new possibilities for "undruggable" targets. Andreas provides insights into the challenges of translating these advancements into real-world therapies, drawing from his deep experience in Big Pharma. Together, they discuss the role of AI in reducing the time and cost of developing new therapies and its potential to reshape the pharmaceutical landscape.

Key Points From This Episode:

• The role of AI in addressing previously "undruggable" targets like GPCRs and ion channels.
• How Absci’s AI-driven approach has shifted from synthetic biology to designing antibodies and biologics for drug discovery.
• The importance of leveraging partnerships with pharma companies like AstraZeneca and Merck to unlock novel biology.
• Andreas Busch’s transition from Big Pharma to Absci, emphasizing how smaller biotech companies attract top talent and foster innovation.
• AI’s role in shortening drug development timelines and reducing costs, allowing companies like Absci to develop differentiated assets faster.
• The blend of best-in-class and first-in-class strategies in Absci’s portfolio, balancing risks in novel biology and proven therapeutic areas.
• How AI models are used to design antibodies with specific affinities and predict drug candidates, a first in antibody drug design.
• The critical role of integrating domain expertise, such as Andreas’s experience in drug development, into AI-driven drug discovery.
• Insights on the future of AI in biology, predicting targets, epitopes, and potential breakthroughs in drug development.
• The importance of talent and culture in building cutting-edge biotech companies.